- Home
- BNC vs BCTX Comparison
BNC vs BCTX Comparison
Compare BNC & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNC
- BCTX
- Stock Information
- Founded
- BNC N/A
- BCTX 2014
- Country
- BNC United States
- BCTX Canada
- Employees
- BNC N/A
- BCTX N/A
- Industry
- BNC Industrial Machinery/Components
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- BNC Industrials
- BCTX Health Care
- Exchange
- BNC Nasdaq
- BCTX Nasdaq
- Market Cap
- BNC 13.7M
- BCTX 14.4M
- IPO Year
- BNC N/A
- BCTX N/A
- Fundamental
- Price
- BNC $17.07
- BCTX $7.72
- Analyst Decision
- BNC
- BCTX Strong Buy
- Analyst Count
- BNC 0
- BCTX 1
- Target Price
- BNC N/A
- BCTX $40.00
- AVG Volume (30 Days)
- BNC 343.8K
- BCTX 92.9K
- Earning Date
- BNC 09-16-2025
- BCTX 10-28-2025
- Dividend Yield
- BNC N/A
- BCTX N/A
- EPS Growth
- BNC N/A
- BCTX N/A
- EPS
- BNC N/A
- BCTX N/A
- Revenue
- BNC $3,478,254.00
- BCTX N/A
- Revenue This Year
- BNC N/A
- BCTX N/A
- Revenue Next Year
- BNC N/A
- BCTX N/A
- P/E Ratio
- BNC N/A
- BCTX N/A
- Revenue Growth
- BNC 10.08
- BCTX N/A
- 52 Week Low
- BNC $5.60
- BCTX $6.00
- 52 Week High
- BNC $82.88
- BCTX $294.00
- Technical
- Relative Strength Index (RSI)
- BNC N/A
- BCTX 40.75
- Support Level
- BNC N/A
- BCTX $7.28
- Resistance Level
- BNC N/A
- BCTX $8.82
- Average True Range (ATR)
- BNC 0.00
- BCTX 0.74
- MACD
- BNC 0.00
- BCTX 0.58
- Stochastic Oscillator
- BNC 0.00
- BCTX 60.82
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.